![Avastin, Herceptin, Rituxan Now Sold Under Tighter Control by Drug Maker](https://cdn.cancerletter.com/media/2024/01/02050657/40-37-Avastin-Herceptin-Rituxan.jpg)
![Avastin, Herceptin, Rituxan Now Sold Under Tighter Control by Drug Maker](https://cdn.cancerletter.com/media/2024/01/02050657/40-37-Avastin-Herceptin-Rituxan.jpg)
Cover Story
A move by Genentech has eliminated discounts and rebates hospitals receive when they purchase three of the company's top-selling infused cancer drugs.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Funding Opportunities
Trending Stories
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care
- Elizabeth Comen joins NYU Langone Health’s Perlmutter Cancer Center
- Trump et al. are wrong: Biden Cancer Initiative is not to be confused with the Beau Biden Cancer Moonshot
- Edward Sondik, electrical engineer turned public health expert and one-time interim NCI director, dies at 82
- A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply
Warning: This is not a public health recommendation. Do not implement.